Patents Assigned to Genentech, Inc.
  • ANTI-LRP6 ANTIBODIES
    Publication number: 20110256127
    Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.
    Type: Application
    Filed: March 23, 2011
    Publication date: October 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
  • 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20110251181
    Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).
    Type: Application
    Filed: January 9, 2009
    Publication date: October 13, 2011
    Applicants: Genentech, Inc., Array BoPharma Inc.
    Inventors: Anna Banka, Josef R. Bencsik, James Blake, Martin Hentermann, Stephen T. Schlachter, Eli M. Wallace, Rui Xu
  • Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
    Patent number: 8034342
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: October 11, 2011
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20110245230
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 6, 2011
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20110246399
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 6, 2011
    Applicants: Genentech, Inc., Hoffmann-La Roche, Inc.
    Inventors: LUKAS C. AMLER, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20110245103
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 6, 2011
    Applicants: Genentech, Inc., Hoffmann-La Roche. Inc.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • APO-2 ligand/trail formulations
    Publication number: 20110245185
    Abstract: The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 6, 2011
    Applicant: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • DR5 antibodies and articles of manufacture containing same
    Patent number: 8029783
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • Anti-hedgehog antibodies
    Patent number: 8030454
    Abstract: The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventor: Suzanna J. Scales
  • Nucleic acid encoding DR5 antibodies and uses thereof
    Patent number: 8030023
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • CDR-REPAIRED ANTIBODIES
    Publication number: 20110237779
    Abstract: The present application concerns restoring antigen binding during humanization of antibodies through the selection of repaired hypervariable regions rather than through framework changes.
    Type: Application
    Filed: November 16, 2010
    Publication date: September 29, 2011
    Applicant: Genentech, Inc.
    Inventor: Mark S. Dennis
  • ANTIBODY FORMULATION
    Publication number: 20110226650
    Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.
    Type: Application
    Filed: December 20, 2010
    Publication date: September 22, 2011
    Applicant: Genentech, Inc.
    Inventors: Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
  • HUMAN GROWTH HORMONE AQUEOUS FORMULATION
    Publication number: 20110230408
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 22, 2011
    Applicant: Genentech, Inc.
    Inventors: Barbara H. O'Connor, James Q. Oeswein
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20110223619
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: May 17, 2011
    Publication date: September 15, 2011
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • AZAINDOLE INHIBITORS OF IAP
    Publication number: 20110218211
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3?, R4, R4?, R5, R6, R6? and R9 are as described herein.
    Type: Application
    Filed: August 14, 2009
    Publication date: September 8, 2011
    Applicant: Genentech, Inc.
    Inventors: Philippe Bergeron, Michael F.T. Koehler
  • Humanized anti-TGF-beta antibodies
    Patent number: 8012482
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Patent number: 8012473
    Abstract: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventor: Menno Van Lookeren Campagne
  • Antibody compositions
    Patent number: 8012754
    Abstract: A process for purifying an antibody is provided. In this process, a mixture containing the antibody and a contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) at low salt concentration. The antibody is eluted from the column in the fraction which does not bind thereto. This process can be preceded and followed by other purification steps.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventors: Ernst H. Rinderknecht, Gerardo A. Zapata
  • Compositions and methods for the diagnosis and treatment of tumors of glial origin
    Patent number: 8008004
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumors of glial origin in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: August 30, 2011
    Assignee: Genentech Inc.
    Inventor: Heidi S. Phillips
  • Treatment of complement-associated disorders
    Patent number: 8007798
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood